Shares of Takeda Pharmaceutical Co. (NYSE:TAK – Get Free Report) hit a new 52-week high on Monday. The company traded as high as $21.75 and last traded at $21.7980, with a volume of 8,578 shares traded. The stock had previously closed at $21.43.
Analyst Upgrades and Downgrades
A number of research analysts have issued reports on TAK shares. Weiss Ratings raised shares of Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, November 3rd. Wall Street Zen cut shares of Takeda Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Zacks Research raised shares of Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy”.
Get Our Latest Stock Report on TAK
Takeda Pharmaceutical Stock Performance
The company has a market capitalization of $69.65 billion, a P/E ratio of 28.57 and a beta of -0.02. The company’s 50 day moving average is $19.40 and its 200-day moving average is $17.78. The company has a current ratio of 1.15, a quick ratio of 0.60 and a debt-to-equity ratio of 0.56.
Insider Buying and Selling at Takeda Pharmaceutical
In other news, insider Lauren Duprey sold 34,535 shares of the business’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $18.54, for a total value of $640,278.90. Following the sale, the insider directly owned 191,522 shares of the company’s stock, valued at $3,550,817.88. The trade was a 15.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Andrew Plump sold 116,191 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $18.49, for a total value of $2,148,371.59. Following the transaction, the insider directly owned 145,465 shares of the company’s stock, valued at approximately $2,689,647.85. This trade represents a 44.41% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 238,974 shares of company stock worth $4,549,461 over the last three months. Company insiders own 0.04% of the company’s stock.
Institutional Investors Weigh In On Takeda Pharmaceutical
Several hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC grew its position in Takeda Pharmaceutical by 14.2% in the 1st quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock worth $55,358,000 after purchasing an additional 370,800 shares during the period. Quantinno Capital Management LP raised its stake in Takeda Pharmaceutical by 20.6% during the 1st quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company’s stock valued at $23,878,000 after buying an additional 219,999 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Takeda Pharmaceutical by 57.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 240,506 shares of the company’s stock valued at $4,375,000 after buying an additional 87,828 shares during the period. Fisher Asset Management LLC bought a new position in shares of Takeda Pharmaceutical during the 3rd quarter valued at $1,582,000. Finally, Point Nemo Capital LLC bought a new position in shares of Takeda Pharmaceutical during the 3rd quarter valued at $1,453,000. 9.17% of the stock is owned by institutional investors.
About Takeda Pharmaceutical
Takeda Pharmaceutical Company is a Japan-based global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Founded in Osaka in 1781 as a medicine wholesaler, it has grown into an international pharmaceutical business headquartered in Tokyo. The company focuses on gastroenterology and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Its portfolio includes treatments for conditions such as inflammatory bowel disease and hereditary angioedema, along with medicines and vaccines across its other therapeutic areas.
Further Reading
- Five stocks we like better than Takeda Pharmaceutical
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
